Sign in Subscribe

article

A collection of 632 issues

Study compares biologic agents in liver-limited RAS wild-type disease

Skip to content The CRC Digest ▸ TREATMENT Study compares biologic agents in liver-limited RAS wild-type disease A retrospective analysis of 241 patients with RAS wild-type metastatic colorectal cancer confined to the liver compared outcomes among patients treated with first-line chemotherapy plus panitumumab, cetuximab, or bevacizumab, evaluating depth of response, objective

Circulating tumor DNA dynamics predict survival in metastatic colorectal cancer

Skip to content The CRC Digest ◇ RESEARCH Circulating tumor DNA dynamics predict survival in metastatic colorectal cancer In a study of 1,391 patients, those with persistent or acquired RAS and BRAF mutations in ctDNA had significantly worse overall survival than patients who maintained wild-type status, suggesting liquid biopsy monitoring

Disrupting KRAS-AGO2 interaction may sensitize KRAS-mutant CRC to therapy

Skip to content The CRC Digest Disrupting KRAS-AGO2 interaction may sensitize KRAS-mutant CRC to therapy Preclinical research developed peptide-gold nanoparticles that disrupt the interaction between mutated KRAS and AGO2, potentially sensitizing KRAS-mutated colorectal cancer to chemo-immunotherapy. (Apoptosis) This content is informational only and does not constitute medical advice. Always consult

HER2 amplification studied in resectable CRC

Skip to content The CRC Digest HER2 amplification studied in resectable CRC A study of 3,607 patients with resectable colorectal cancer investigated the prognostic impact of WES-defined ERBB2 amplification and its association with adjuvant chemotherapy efficacy and circulating tumor DNA. (Int J Clin Oncol) This content is informational only

New ctDNA assay validated for minimal residual disease monitoring across solid tumors

Skip to content The CRC Digest ◇ RESEARCH New ctDNA assay validated for minimal residual disease monitoring across solid tumors The Haystack MRD assay, a tumor-informed ctDNA test that tracks patient-specific somatic mutations, has been analytically and clinically validated across 23 solid tumor types for detecting minimal residual disease at low

Prophylactic HIPEC analyzed for survival outcomes in locally advanced colorectal cancer

Skip to content The CRC Digest ▸ TREATMENT Prophylactic HIPEC analyzed for survival outcomes in locally advanced colorectal cancer A meta-analysis of 2,023 patients analyzed prophylactic hyperthermic intraperitoneal chemotherapy in patients with locally advanced colorectal cancer, extracting and pooling data to analyze peritoneal metastasis-free survival, disease-free survival, and overall survival.

ctDNA methylation profiling may predict prognosis beyond mutation testing

Skip to content The CRC Digest ◇ RESEARCH ctDNA methylation profiling may predict prognosis beyond mutation testing DNA methylation in circulating tumor DNA may provide additional prognostic information beyond mutation-based analysis by reflecting coordinated regulatory states associated with tumor behavior, including transcriptional programs and cellular plasticity. (Epigenomics) This content is informational

Inadequate bowel prep obscures polyps and early cancer signs, increases costs

Skip to content The CRC Digest ▪ SCREENING Inadequate bowel prep obscures polyps and early cancer signs, increases costs A new guideline emphasizes that inadequate bowel preparation can obscure polyps, lesions, or early signs of colorectal cancer while increasing procedure length and shortening surveillance intervals; experts recommend aiming for adequate prep

Immunotherapy combinations tested in pMMR/MSS rectal cancer

Skip to content The CRC Digest Immunotherapy combinations tested in pMMR/MSS rectal cancer Meta-analysis evaluates immune checkpoint inhibitor-based neoadjuvant therapy for proficient mismatch repair and microsatellite stable locally advanced rectal tumors. (Clinical Colorectal Cancer) This content is informational only and does not constitute medical advice. Always consult your oncologist

Study identifies risk factors for irinotecan liver toxicity

Skip to content The CRC Digest ♥ LIVING WITH CRC Study identifies risk factors for irinotecan liver toxicity A retrospective study of 229 cancer patients receiving irinotecan chemotherapy identified key risk factors for hepatotoxicity, which could help clinicians monitor and manage this side effect more effectively. (Frontiers in Oncology) This content